SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
APPLIED DNA SCIENCES, INC.
---------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.0001
---------------------------------------------------------------------
(Title of Class of Securities)
03815U 10 2
---------------------------------------------------------------------
(CUSIP Number)
Lawrence "Larry" Lee
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
December 15, 2002
-----------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f)
or Rule 13d-1(g), check the following box [].
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See Rule 13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
CUSIP NO.
03815U 10 2
SCHEDULE 13D
---------------------------- ----------------
CUSIP NO. 03815U 10 2 PAGE 2 OF 5 PAGES
---------------------------- ----------------
---------------------------------------------------------------------
--
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Larry Lee n/a
-----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(A) [ ]
(B) [ ]
---------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
---------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e)
---------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
---------------------------------------------------------------------
7 SOLE VOTING POWER
4,820,000
NUMBER OF -------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY - 0 -
EACH -----------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 4,820,000
-----------------------------------------------------
10 SHARED DISPOSITIVE POWER
- 0 -
---------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,820,000
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions) [ ]
---------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.4%
---------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
---------------------------------------------------------------------
ITEM 1. SECURITY AND ISSUER.
This Statement relates to shares of common stock, $0.0001 par value
per share (the "Common Stock"), of APPLIED DNA SCIENCES, INC. (the
"Corporation"). The Corporation's principal executive office is
located at 8233 Roxbury Road Los Angeles, CA 90069
ITEM 2. IDENTITY AND BACKGROUND.
(a) This Statement is being filed by RHL Management, Inc. (the
"Reporting Person").
(b) The business address of the Reporting Person is:
9225 West Sunset Blvd., Suite 805, Los Angeles, California 90096
(c) The Reporting Person's present principal occupation is:
President
(d) During the past five years, Mr. Lawrence Lee has not been
convicted in a criminal proceeding.
(e) During the last five years, Mr. Lee has not been a party to
a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding been
subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to,
federal or state securities law or finding any violation with
respect to such law.
(f) The Reporting Person is a citizen of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The Reporting entity initially acquired a total of 5,500,000 shares
of Common Stock of the Company in a Plan and Agreement of
Reorganization between the shareholders of Applied DNA Sciences, Inc.
(of which the reporting entity was one of two) and ProHealth Medical
Technologies, Inc. After the reorganization, ProHealth Medical
Technologies, Inc. was renamed Applied DNA Sciences, Inc.
ITEM 4. PURPOSE OF TRANSACTION.
The Reporting Person has acquired his beneficial ownership in the
shares of Common Stock in a Reorganization classified under the
I.R.C. as a 368(a)1(B) Plan and Agreement of Reorganization. The
transaction was a tax free, stock for stock exchange. The total
shares issued by ProHealth Medical Technologies, Inc. in that
transaction were 11,000,000: 5,500,000 to RHL Management, Inc; and
5,500,000 to Lawrence Lee, the two shareholders of Applied DNA
Sciences, Inc. Subsequent to that transaction, RHL Management, Inc.
and Lawrence Lee transferred 180,000 and 680,000 shares,
respectively, to a company treasury account entitled "Applied DNA
Sciences, Inc. Hiring Incentive Treasury Account" which shares are to
be used from time to time to entice new management and employees to
join the Company. After the aforementioned reorganization was
effectuated, the corporate name of ProHealth Medical Technologies,
Inc. was changed to Applied DNA, Sciences, Inc. The Reporting Person
does not have any present plan or proposal as a stockholder which
relates to, or would result in any action with respect to, the
matters listed in paragraphs (b) through (j) of Item 4 of Schedule
13D. In the future, the Reporting Person may decide to purchase
additional shares of Common Stock in the open market or a private
transaction, or to sell any or all of his shares of Common Stock.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
a) As of December 15, 2002, the corporation had issued and
outstanding a total of 21,551,640 shares of Common Stock. As of that
date, the Reporting Person was the beneficial owner of 4,820,000
shares of Common Stock or 22.4% of the issued and outstanding Common
Stock.
(b) The Reporting Person has the sole power to vote, or to direct the
vote of, 4,820,000 shares of Common Stock and sole power to dispose
of, or to direct the disposition of 4,820,000 shares of Common Stock.
(c) The Reporting Person initially acquired 5,500,000 shares in a
Plan and Agreement of Reorganization under Section 368 (a)(1)B of the
Internal Revenue Code between the shareholders of Applied DNA
Sciences, Inc. and ProHealth Medical Technologies, Inc. (the former
name of the reporting Nevada corporation, Applied DNA Sciences, Inc.)
(d) Not applicable.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR
RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
Not applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
There are no purchases or sales to disclose at this time.
SIGNATURE.
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
Dated: January 15, 2003
By: /s/Larry Lee
Larry lee